SVRE vs AEYE vs CELU vs ALKT vs FATE

For growth investors, Alkami Technology, Inc.

(ALKT) is the stronger pick with 32. 9% revenue growth year-over-year, versus -51. 2% for Fate Therapeutics, Inc. (FATE). Analysts rate Alkami Technology, Inc. (ALKT) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Alkami Technology, Inc.

(ALKT) delivered a total return of -53. 8%, compared to -100. 0% for SaverOne 2014 Ltd (SVRE). Over 10 years, the gap is even starker: AEYE returned +96. 5% versus SVRE's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Alkami Technology, Inc.

(ALKT) is the lower-risk stock at 1. 23β versus AudioEye, Inc. 's 2. 18β — meaning AEYE is approximately 77% more volatile than ALKT relative to the S&P 500. On balance sheet safety, AudioEye, Inc. (AEYE) carries a lower debt/equity ratio of 15% versus 98% for Alkami Technology, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Alkami Technology, Inc.

(ALKT) is pulling ahead at 32. 9% versus -51. 2% for Fate Therapeutics, Inc. (FATE). On earnings-per-share growth, the picture is similar: SaverOne 2014 Ltd grew EPS 72. 2% year-over-year, compared to -35. 7% for Celularity Inc.. Over a 3-year CAGR, SVRE leads at 55. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

AudioEye, Inc.

(AEYE) is the more profitable company, earning -7. 6% net margin versus -20. 8% for SaverOne 2014 Ltd — meaning it keeps -7. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AEYE leads at -7. 9% versus -22. 2% for FATE. At the gross margin level — before operating expenses — AEYE leads at 78. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for FATE: 1552.

7% to $39. 50.

In this comparison, CELU (26.

2% yield) pays a dividend. SVRE, AEYE, ALKT, FATE do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Celularity Inc.

(CELU) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (26. 2% yield). Fate Therapeutics, Inc. (FATE) carries a higher beta of 1. 99 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CELU: -99. 1%, FATE: +38. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SVRE (Technology) and AEYE (Technology) and CELU (Healthcare) and ALKT (Technology) and FATE (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SVRE is a small-cap quality compounder stock; AEYE is a small-cap quality compounder stock; CELU is a small-cap income-oriented stock; ALKT is a small-cap high-growth stock; FATE is a small-cap quality compounder stock. CELU pays a dividend while SVRE, AEYE, ALKT, FATE do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.